Novel Immunotherapies for T Cell Lymphoma and Leukemia.

ABSTRACT:

Purpose of review

Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia.

Recent findings

For T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, eith

SUBMITTER: Ghione P 

PROVIDER: S-EPMC6295363 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature